FDA, Genentech warn on Raptiva

The FDA announced new warnings on the Genentech psoriasis drug Raptiva following reports of four cases of hemolytic anemia diagnosed four to six months after patients started on the monoclonal antibody. Two of the cases occurred in clinical trials of Raptiva, and two were reported as post-marketing events, the FDA said.

- read this press release for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.